Press Releases

Date Title and Summary Additional Formats
Toggle Summary Xencor Doses First Patient in Phase 1 Study of XmAb®22841 for the Treatment of Patients with Advanced Solid Tumors
— XmAb22841, a CTLA-4 x LAG-3 bispecific antibody, is Xencor’s third tumor microenvironment (TME) activator to enter clinical development — — Phase 1 study to explore the combination of XmAb22841 with pembrolizumab, an anti-PD-1 immunotherapy, to create triple checkpoint blockade — MONROVIA, Calif.
View HTML
Toggle Summary Xencor Appoints Jeremy Grunstein, Ph.D., as Vice President, Business Development
MONROVIA, Calif. --(BUSINESS WIRE)--May 23, 2019-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced the appointment of Jeremy Grunstein
View HTML
Toggle Summary Xencor Reports First Quarter 2019 Financial Results
-- Management to Host Conference Call at 4:30 p.m. ET today -- MONROVIA, Calif. --(BUSINESS WIRE)--May 9, 2019-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic
View HTML
Toggle Summary Xencor to Present at Upcoming Investor Conferences
MONROVIA, Calif. --(BUSINESS WIRE)--May 8, 2019-- Xencor, Inc.  (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and allergic diseases, today announced that company management will present
View HTML
Toggle Summary Xencor Doses First Patient in Phase 1 Study of XmAb®23104 for the Treatment of Patients with Advanced Solid Tumors
— XmAb23104, a PD-1 x ICOS bispecific antibody, is the sixth XmAb ® antibody engineered with Xencor’s bispecific Fc domain to enter clinical development — MONROVIA, Calif. --(BUSINESS WIRE)--May 6, 2019-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered
View HTML
Toggle Summary Xencor to Host First Quarter 2019 Financial Results Webcast and Conference Call on May 9, 2019
MONROVIA, Calif. --(BUSINESS WIRE)--May 2, 2019-- Xencor, Inc.  (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced that it will release first quarter
View HTML
Toggle Summary Xencor Announces Partial Clinical Hold Lifted on Phase 1 Study of XmAb®14045
MONROVIA, Calif. --(BUSINESS WIRE)--Apr. 30, 2019-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced the U.S.
View HTML
Toggle Summary Xencor and Astellas Enter Collaboration for Novel Bispecific Antibody Program
-- Partners to Generate Novel Bispecific Antibodies Directed Toward an Anti-tumor Target Identified by Astellas -- -- Astellas to Receive Exclusive Worldwide License to Potential Drug Candidates -- MONROVIA, Calif. --(BUSINESS WIRE)--Apr. 2, 2019-- Xencor, Inc.
View HTML
Toggle Summary Xencor to Participate in Upcoming Investor Conferences
MONROVIA, Calif. --(BUSINESS WIRE)--Apr. 1, 2019-- Xencor, Inc.  (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and allergic diseases, today announced that company management will
View HTML
Toggle Summary Xencor Announces Closing of Research Collaboration and License Agreement with Genentech
MONROVIA, Calif. --(BUSINESS WIRE)--Mar. 8, 2019-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune disease, asthma and allergic diseases, and cancer, today announced the closing of its research
View HTML
Xencor © Copyright 2019